8 nominees · 3 ballot items.
Election of eight directors; Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal 2027; Advisory vote to approve, on a non-binding basis, Named Executive Officer compensation.
Elect eight director nominees named in the Proxy Statement to serve one-year terms ending in 2027.
Ratify the Audit Committee’s appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending January 2, 2027.
A non-binding, advisory vote to approve the compensation of the company’s Named Executive Officers as disclosed in the Proxy Statement (Say-on-Pay).
This management proposal requests an annual, non-binding advisory approval (Say-on-Pay) of the Named Executive Officers’ compensation as disclosed in the Proxy Statement. Management and the Compensation Committee argue that the compensation program is designed to align executive incentives with long-term stockholder value through a pay-for-performance philosophy emphasizing performance-based equity (PRSUs tied to TSR and revenue growth), a Corporate Incentive Plan with revenue and non-GAAP operating income metrics, and retention/grant actions following leadership changes. The Board recommends a vote FOR, noting responsiveness to the 2025 Say-on-Pay outcome (~56% support) and subsequent extensive stockholder outreach leading to enhanced disclosures and guardrails. Key context includes multi-year CEO hiring awards (no CEO equity grants in 2025), significant use of revenue-growth-linked PRSUs and the Go for Gold program to broaden top-line alignment, and the Compensation Committee’s discretion (e.g., no discretionary adjustments to 2025 payouts). Counterarguments for shareholders could include concerns over special/one-time grants, the prior low Say-on-Pay support, and the heavy emphasis on revenue which may underweight margin or profitability metrics; management addressed this by keeping margin/operating income in the Corporate Incentive Plan and implementing governance safeguards like clawback and stock ownership policies.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 11.86% | 16,243,449 | $1.5B |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.63% | 15,939,710 | $1.5B |
| 3 | BlackRock, Inc. | 7.28% | 9,978,727 | $926M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.40% | 7,400,887 | $687M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.49% | 6,145,510 | $570M |
| 6 | Invesco Ltd. | 3.95% | 5,414,124 | $502M |
| 7 | STATE STREET CORP | 3.37% | 4,613,504 | $428M |
| 8 | Capital Research Global Investors | 3.17% | 4,336,947 | $402M |
| 9 | BlackRock, Inc. | 2.93% | 4,017,539 | $373M |
| 10 | FRANKLIN RESOURCES INC | 2.54% | 3,475,045 | $322M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.